These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 17287412

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [Abstract] [Full Text] [Related]

  • 8. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
    Shimon I, Sosa E, Mendoza V, Greenman Y, Tirosh A, Espinosa E, Popovic V, Glezer A, Bronstein MD, Mercado M.
    Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas.
    Pontikides N, Krassas GE, Nikopoulou E, Kaltsas T.
    Pituitary; 2000 May; 2(4):277-81. PubMed ID: 11081149
    [Abstract] [Full Text] [Related]

  • 11. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
    Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K.
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4721-7. PubMed ID: 18812485
    [Abstract] [Full Text] [Related]

  • 12. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
    Phillips J, East HE, French SE, Melcescu E, Hamilton RD, Nicholas WC, Fratkin JF, Parent AD, Luzardo G, Koch CA.
    Hormones (Athens); 2012 Dec; 11(4):477-82. PubMed ID: 23422771
    [Abstract] [Full Text] [Related]

  • 13. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
    Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B, Delemer B, Ciccarelli E, Beck-Peccoz P, Caron P, Daly AF, Beckers A.
    Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
    Hacisahinogullari H, Canturk S, Dogansen S, Yarman S.
    J Fr Ophtalmol; 2022 May; 45(5):511-518. PubMed ID: 35272874
    [Abstract] [Full Text] [Related]

  • 17. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
    Cannavò S, Curtò L, Squadrito S, Almoto B, Vieni A, Trimarchi F.
    J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.